IL130762A - Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia - Google Patents

Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia

Info

Publication number
IL130762A
IL130762A IL13076298A IL13076298A IL130762A IL 130762 A IL130762 A IL 130762A IL 13076298 A IL13076298 A IL 13076298A IL 13076298 A IL13076298 A IL 13076298A IL 130762 A IL130762 A IL 130762A
Authority
IL
Israel
Prior art keywords
medicaments
quinoline
manufacture
preparation
treatment
Prior art date
Application number
IL13076298A
Other languages
English (en)
Other versions
IL130762A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL130762A0 publication Critical patent/IL130762A0/xx
Publication of IL130762A publication Critical patent/IL130762A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13076298A 1997-01-11 1998-01-06 Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia IL130762A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (2)

Publication Number Publication Date
IL130762A0 IL130762A0 (en) 2001-01-28
IL130762A true IL130762A (en) 2005-12-18

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13076298A IL130762A (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia

Country Status (45)

Country Link
US (4) US6169093B1 (zh)
EP (1) EP0968208B1 (zh)
JP (1) JP3357677B2 (zh)
KR (1) KR100347472B1 (zh)
CN (2) CN1093858C (zh)
AP (1) AP819A (zh)
AR (1) AR010396A1 (zh)
AT (1) ATE242238T1 (zh)
AU (1) AU724990B2 (zh)
BG (1) BG63918B1 (zh)
BR (1) BR9807068A (zh)
CA (1) CA2277473C (zh)
CZ (1) CZ295580B6 (zh)
DE (1) DE69815313T2 (zh)
DK (1) DK0968208T3 (zh)
DZ (1) DZ2394A1 (zh)
EA (1) EA002851B1 (zh)
ES (1) ES2198695T3 (zh)
GB (1) GB9700504D0 (zh)
HK (2) HK1025327A1 (zh)
HN (1) HN1998000002A (zh)
HR (1) HRP980010B1 (zh)
HU (1) HUP0000942A3 (zh)
ID (1) ID21863A (zh)
IL (1) IL130762A (zh)
IS (1) IS2012B (zh)
MA (1) MA26465A1 (zh)
MY (1) MY119623A (zh)
NO (1) NO318609B1 (zh)
NZ (1) NZ336302A (zh)
OA (1) OA11074A (zh)
PA (1) PA8444301A1 (zh)
PE (1) PE44499A1 (zh)
PL (1) PL334678A1 (zh)
PT (1) PT968208E (zh)
SA (1) SA97180705B1 (zh)
SI (1) SI0968208T1 (zh)
SK (1) SK284779B6 (zh)
TN (1) TNSN98004A1 (zh)
TR (1) TR199901604T2 (zh)
TW (1) TW444013B (zh)
UA (1) UA62945C2 (zh)
WO (1) WO1998030560A1 (zh)
YU (1) YU31699A (zh)
ZA (1) ZA98166B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
TR200302130T4 (tr) * 2000-03-03 2004-01-21 Pfizer Inc. 4-Amino-6,7-Demetoksi-2- (5-Metansulfonamido-1,2,3,4-Tetrahidroisokinol-2-İl) -5-(2-Piridil) Kinazolin Mesilat ve Polimorflar
JP3971299B2 (ja) 2000-08-31 2007-09-05 エフ．ホフマン−ラ ロシュ アーゲー α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
BR0314759A (pt) 2002-09-26 2005-07-26 Pfizer Derivados de pirazol
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
RU2006102867A (ru) * 2003-07-02 2007-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 5-замещенного хиназолинона
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
NZ724691A (en) * 2014-03-24 2018-02-23 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
GR79603B (zh) 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
MY119623A (en) 2005-06-30
YU31699A (sh) 2001-07-10
US6365599B1 (en) 2002-04-02
EP0968208A1 (en) 2000-01-05
US6521629B2 (en) 2003-02-18
WO1998030560A1 (en) 1998-07-16
BG103560A (en) 2000-06-30
HK1025327A1 (en) 2000-11-10
HN1998000002A (es) 1999-01-08
HUP0000942A2 (hu) 2001-04-28
BR9807068A (pt) 2000-05-02
CA2277473A1 (en) 1998-07-16
IL130762A0 (en) 2001-01-28
SI0968208T1 (en) 2003-10-31
IS2012B (is) 2005-05-13
CN1191249C (zh) 2005-03-02
HRP980010B1 (en) 2002-06-30
CZ9902436A3 (cs) 2000-10-11
DE69815313D1 (de) 2003-07-10
BG63918B1 (bg) 2003-06-30
NO318609B1 (no) 2005-04-18
KR100347472B1 (ko) 2002-08-07
SK90799A3 (en) 2001-03-12
DZ2394A1 (fr) 2003-06-04
EA199900531A1 (ru) 2000-02-28
SA97180705B1 (ar) 2005-12-26
DK0968208T3 (da) 2003-07-28
TNSN98004A1 (fr) 2005-03-15
JP3357677B2 (ja) 2002-12-16
DE69815313T2 (de) 2003-12-11
OA11074A (en) 2002-03-13
HRP980010A2 (en) 1998-10-31
UA62945C2 (en) 2004-01-15
US6653302B2 (en) 2003-11-25
SK284779B6 (sk) 2005-11-03
ES2198695T3 (es) 2004-02-01
HK1054389B (zh) 2005-10-14
GB9700504D0 (en) 1997-02-26
AU724990B2 (en) 2000-10-05
PA8444301A1 (es) 2000-05-24
ATE242238T1 (de) 2003-06-15
NO993396D0 (no) 1999-07-09
PE44499A1 (es) 1999-05-06
CZ295580B6 (cs) 2005-08-17
AU6208898A (en) 1998-08-03
KR20000070022A (ko) 2000-11-25
AP819A (en) 2000-04-03
CA2277473C (en) 2003-08-12
TR199901604T2 (xx) 1999-12-21
US20020040028A1 (en) 2002-04-04
ZA98166B (en) 1999-07-09
NO993396L (no) 1999-07-09
CN1093858C (zh) 2002-11-06
US6169093B1 (en) 2001-01-02
EA002851B1 (ru) 2002-10-31
IS5093A (is) 1999-06-25
PT968208E (pt) 2003-09-30
NZ336302A (en) 2000-08-25
EP0968208B1 (en) 2003-06-04
TW444013B (en) 2001-07-01
MA26465A1 (fr) 2004-12-20
CN1243513A (zh) 2000-02-02
HK1054389A1 (en) 2003-11-28
JP2000507966A (ja) 2000-06-27
HUP0000942A3 (en) 2002-06-28
ID21863A (id) 1999-08-05
PL334678A1 (en) 2000-03-13
AP9801175A0 (en) 1998-01-31
CN1403453A (zh) 2003-03-19
US20030130259A1 (en) 2003-07-10
AR010396A1 (es) 2000-06-07

Similar Documents

Publication Publication Date Title
IL130762A (en) Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
IL149034A (en) Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeabiltiy reducing effect
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0105133A3 (en) Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
EP1045636A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
HUP0004286A3 (en) Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105114A3 (en) Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation
HUP9903732A3 (en) Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
CZ20011652A3 (cs) Farmaceutický přípravek zahrnující moxifloxacin, způsob výroby a použití tohoto přípravku
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
PL312079A1 (en) Derivatives of 3-phenyl isoquinolin-1 (2h)-one, method of obtaining them, therapeutic agent and pharmaceutical composition
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
EP0799619A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia
NO307930B1 (no) Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
HUP0103832A3 (en) Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees